Blog

Lunch is on Us! Schedule a Virtual Lunch-N-Learn with the CuriRx, Inc.’s Team to learn how our CDMO services can help you accelerate drug development. Choose 1 Service Area or All 3: Analytical Development and Testing Services • Method Development, Qualification, Phase Appropriate Validation • Non-GMP and GMP testing and Stability Studies • Product & Drug Substance Release Testing • CMC Testing & Characterization using CuriLytics™ Platform Complex Formulation Services • Pre-Formulation, Formulation Development, Dosage

Peptide Mapping Challenges That An Experienced CDMO Can Solve Peptide mapping using mass spectrometry is a powerful technique for analyzing proteins,  with several challenges that must be navigated. CuriRx effectively and efficiently mitigates all of these challenges by applying multiple techniques based on a wealth of experience in biologics characterization. Here are some of the challenges and CuriRx’s novel approach. Optimized sequence coverage: Large hydrophobic regions can be particularly problematic. We solve this by first

WILMINGTON, MA, August 27, 2024— We are excited to introduce the new CuriRx, Inc. Newsletter! Stay informed with the latest industry developments, highlights from client projects, upcoming events, our range of service offerings, and much more.  LINK TO Newsletter CuriRx: is a leading Contract Research, Development and Manufacturing Organization (CRDMO) based in Massachusetts, consisting of a minority female entrepreneur and a group of experts with diverse backgrounds. The company specializes in bioprocessing, formulation, and analytical

WILMINGTON, MA, September 12, 2023— CuriRx, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) based in Massachusetts, is thrilled to announce its participation in the upcoming Bioprocessing International Conference(BPI) at the Boston Convention and Exhibition Center from September 18-21. The event, renowned as the largest gathering in the bioprocessing industry, provides an exceptional platform for professionals to accelerate the journey of promising biologics, cell therapies, and gene therapies toward commercial success. CuriRx welcomes any